Tarlatamab

2024 saw significant advances in cancer research, including a 100% complete response rate in a dostarlimab trial for rectal cancer, FDA approvals for immunotherapies, and progress in early detection and prevention. Telehealth also showed promise in improving cancer care.

Experts discuss strategies for dynamic clinical pathways, challenges in payer pathways, cost considerations, and the impact of accelerated drug approvals. Organizations like OneOncology, Dana-Farber Cancer Institute, and Florida Cancer Specialists emphasize participation, consistency, and adaptability in pathway development. Drug shortages and payer lag behind innovation are significant challenges. Effective communication, education, and cost considerations are crucial for pathway success.

2024 saw significant advances in cancer research, including personalized neoantigen vaccines, AI in drug discovery, and first-in-class therapeutics. Progress was also made in early detection, overcoming resistance, and addressing cancer health disparities.

Accelerated FDA approvals bring hope for small-cell lung cancer (SCLC) treatments like tarlatamab, though caution is advised due to potential withdrawal risks. The NRG Oncology/Alliance LU005 trial found no survival benefit from adding atezolizumab to standard chemoradiotherapy in LS-SCLC, but twice-daily radiation showed improved survival.

New therapies and immunotherapies have significantly improved lung cancer survival. Sylvester researchers advocate for ensuring all patients benefit from advancements, including targeted therapies for small-cell tumors. Better screening and addressing disparities are crucial for future progress.

This review examines 10 years of BiTE immunotherapy, focusing on pancreatic cancer. It discusses the development of BiTEs, their therapeutic features, manufacturing challenges, and strategies for improving their efficacy in solid tumors like pancreatic cancer, drawing lessons from their use in other cancers.

The 22nd Annual Winter Lung Cancer Conference will focus on advances in neoadjuvant/adjuvant immunotherapy for early-stage NSCLC. FDA approved obecabtagene autoleucel for relapsed/refractory B-ALL, and new therapies like lurbinectedin and tarlatamab are transforming SCLC treatment. Real-world data shows apalutamide improves survival over enzalutamide in prostate cancer. LBL-034, a GPRC5D-targeting bispecific antibody, received orphan drug designation for multiple myeloma.

Lung cancer treatment advances include minimally invasive surgery, targeted therapies, immunotherapies, and genetic testing at MSK. New treatments like KRAS inhibitors and TIL therapy show promise. Early detection through screening and innovative methods like E-nose and liquid biopsies aim to improve survival rates.

Recent SCLC treatments include FDA approval of tarlatamab-dlle, positive trial results, and new agents like lurbinectedin. Immunotherapies atezolizumab and durvalumab improve survival but lack predictive biomarkers. Surgical options are limited to early-stage cases. Novel agents are more tolerable, shifting treatment paradigms.

New research on small cell lung cancer (SCLC) highlights potential for personalized therapies targeting DLL3 and TTF-1 biomarkers, improving patient outcomes.